This article is a follow up on discussions had in Noordwijk-aan-Zee about how to accelerate R&D in the neglected and emerging infectious diseases. 

 

The two articles, one by Bénédicte Callan and Iain Gillespie of the OECD Biotechnology Division and the other by Anthony Hopkins, Salomon Nwaka and Michael Witty, are sister articles that were developed together and provide two complementary perspectives on the challenges identified in the Noordwijk Medicines Agenda.

 

To review all articles, please click on: http://www.nature.com/nature/outlook/neglecteddiseases/index.html